Wire Stories
Genexine�s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera
SEOUL, South Korea–(BUSINESS WIRE)–A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG...